Literature DB >> 21182075

Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome.

Alexandre Dalet1, Vincent Stroobant, Nathalie Vigneron, Benoît J Van den Eynde.   

Abstract

Peptide splicing allows the production of antigenic peptides composed of two fragments initially non-contiguous in the parental protein. The proposed mechanism of splicing is a transpeptidation occurring within the proteasome. Three spliced peptides, derived from FGF-5, melanoma protein gp100 and nuclear protein SP110, have been described. Here, we compared the production of these spliced peptides by the standard proteasome and the immunoproteasome. Differential isotope labelling was used to quantify (by mass spectrometry) the fragments contained in digests obtained with precursor peptides and purified proteasomes. The results show that both the standard and the immunoproteasomes can produce spliced peptides although they differ in their efficiency of production of each peptide. The FGF-5 and gp100 peptides are more efficiently produced by the standard proteasome, whereas the SP110 peptide is more efficiently produced by the immunoproteasome. This seems to result from differences in the production of the two splicing partners, which depends on a balance between cleavages liberating or destroying those fragments. By showing that splicing depends on the efficiency of production of the splicing partners, these results also support the transpeptidation model of peptide splicing. Furthermore, given the presence of immunoproteasomes in dendritic cells and cells exposed to IFN-γ, the findings may be relevant for vaccine design.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21182075     DOI: 10.1002/eji.201040750

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

Review 1.  Database of T cell-defined human tumor antigens: the 2013 update.

Authors:  Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Cancer Immun       Date:  2013-07-15

Review 2.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Authors:  Alexandre Dalet; Paul F Robbins; Vincent Stroobant; Nathalie Vigneron; Yong F Li; Mona El-Gamil; Ken-ichi Hanada; James C Yang; Steven A Rosenberg; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 4.  Peptide splicing by the proteasome.

Authors:  Nathalie Vigneron; Violette Ferrari; Vincent Stroobant; Joanna Abi Habib; Benoit J Van den Eynde
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

Review 5.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

6.  Towards a liquid self: how time, geography, and life experiences reshape the biological identity.

Authors:  Andrea Grignolio; Michele Mishto; Ana Maria Caetano Faria; Paolo Garagnani; Claudio Franceschi; Paolo Tieri
Journal:  Front Immunol       Date:  2014-04-09       Impact factor: 7.561

Review 7.  Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Biomolecules       Date:  2014-11-18

8.  The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing.

Authors:  Kathrin Textoris-Taube; Christin Keller; Juliane Liepe; Petra Henklein; John Sidney; Alessandro Sette; Peter M Kloetzel; Michele Mishto
Journal:  J Biol Chem       Date:  2015-10-27       Impact factor: 5.157

9.  ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

Authors:  Ramona Clemen; Sander Bekeschus
Journal:  Vaccines (Basel)       Date:  2021-05-19

10.  Response: Commentary: An In Silico-In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.

Authors:  Michele Mishto; Guillermo Rodriguez-Hernandez; Jacques Neefjes; Henning Urlaub; Juliane Liepe
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.